Amgen in Thousand Oaks and the Israeli firm Megapharm have signed an agreement granting Megapharm certain rights to sell Aranesp in Israel.
Aranesp currently is under review by the U. S. Food and Drug Administration and the European Medicine Evaluation Agency for the treatment of anemia associated with chronic renal failure.
Amgen said the drug may treat anemia with less-frequent doses than Epoetin alfa, thereby simplifying anemia management for physicians and leading to more patients being treated.
Last month, Amgen reached an agreement with another company for the distribution of Aranesp in Greece and Cyprus.
Megapharm is based in Hod-Hasharon, Israel.